In-Vitro Acetylcholine Esterase Enzyme Inhibition Potential of Siddha Formulation Vilvaver Chooranam: A Neuroprotective Assay
Keywords:Alzheimer's disease, Siddha, Vilvaver Chooranam, Acetylcholinesterase, Ellman’s method
Background and Aim: Alzheimer's disease (AD) is a progressive neurodegenerative condition evidenced by significant cognitive dysfunction. The state of cognitive impairment is made worse by increased levels of the enzyme acetylcholinesterase (AChE), which is crucial in the hydrolysis of the neurotransmitter acetylcholine (ACh). Siddha therapy gaining higher momentum in recent days due to its global acceptance considering its broad spectral safety and therapeutic window. Siddha originated from the southern geographic landscape of Asia now spreading its wings across the bounders in managing dreadful diseases like AD. The main objective of the present study is to evaluate AChE inhibition of the Siddha formulation Vilvaver Chooranam (VVC). Materials & Methods: In-Vitro Acetylcholine esterase enzyme inhibition Potential of Siddha formulation Vilvaver Chooranam by Ellman’s method. Results:Results obtained from the study clearly demonstrate that the formulation VVC has shown promising acetylcholinesterase at stipulated concentration dose-dependently. Maximum percentage inhibition of about 54.53 ± 3.475 % was observed at 500μg/ml with the IC50 value of 411.9 ± 30.6 µg/ml when compared to that of the Physostigmine, a known AChE Inhibitor with a maximum inhibition 93.44 ± 4.434 % at the concentration of 40μg/ml with the IC50 value of 10.38± 5.29 µg/ml. Conclusion: These findings demonstrate the remarkable potential of these extracts as valuable sources of antioxidants with interesting acetylcholinesterase inhibitory activity.
How to Cite
Copyright (c) 2024 International Journal of Ayurvedic Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
The author hereby transfers, assigns, or conveys all copyright ownership to the International Journal of Ayurvedic Medicine (IJAM). By this transfer, the article becomes the property of the IJAM and may not be published elsewhere without written permission from the IJAM.
This transfer of copyright also implies transfer of rights for printed, electronic, microfilm, and facsimile publication. No royalty or other monetary compensation will be received for transferring the copyright of the article to the IJAM.
The IJAM, in turn, grants each author the right to republish the article in any book for which he or she is the author or editor, without paying royalties to the IJAM, subject to the express conditions that (a) the author notify IJAM in advance in writing of this republication and (b) a credit line attributes the original publication to IJAM.